Piribo: Cancer Biomarkers: Enhancing diagnostic, therapeutic and developmental strategies

The current focus on biomarker discovery is a result of an improved understanding of the biologic basis for carcinogenesis. The increasing number of potential drug targets and a plethora of diverse, new developmental agents have stimulated the search for biomarkers that can reduce the time, cost and attrition rates prevalent in oncology drug development.

It is hoped that the increased adoption of biomarker use in oncology will enable early proof-of-concept studies for novel therapeutic targets; accelerate the adoption of population-enrichment strategies for clinical trial recruitment; and increase the use of biomarker endpoints as surrogates for clinical benefit in oncology clinical trials.

Advances in imaging analysis technology have shed new light on cancer progression by enabling the precise measurement of small changes in structure and function over time. Image-based biomarkers have been singled out by the FDA as promising tools for every stage of drug development, from preclinical research to the approval process.

While targeting specific genotypes in clinical trials increases the opportunity to demonstrate clinical benefit, developers are concerned about how an increasingly fragmented cancer market may limit a drug's commercial potential. There is already skepticism among physicians about how readily Pharma will adopt a more 'personalized' approach.

“Cancer Biomarkers: Enhancing diagnostic, therapeutic and developmental strategies” is available in hard copy and PDF format from Piribo. For more information go to: http://www.piribo.com/search/results.html?k=DAT496&x=3&y=11

Piribo Product Code: DAT496

About Piribo.
Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,500 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.